Switzerland warns against using ‘Lemon Bottle’ fat-dissolving injections
Sample of “Lemon Bottle” lipolysis solution analysed in the official Swissmedic laboratory. None of the ingredients listed on the packaging could be detected.
Swissmedic
Switzerland's drug regulator Swissmedic has issued a warning about the “Lemon Bottle” fat-burning jab which has taken social media by storm. It advises against using the product which has “no medicinal effect”.
This content was published on
2 minutes
Keystone-SDA
In a statement on Tuesday, the Swiss Agency for Therapeutic Products (Swissmedic) warned against using “Lemon Bottle” lipolysis solution.
“No medicinal effect has been scientifically proven, the quality of the ingredients has not been tested and using the product may therefore pose a health risk,” it said.
Swissmedic classifies “Lemon Bottle” as a medicinal product because of its composition and the way it is administered by injection. The product has been promoted on social networks such as TikTok and the internet for its effects in reducing fat deposits on the face and certain parts of the body.
The Swiss regulator has analysed “Lemon Bottle” samples injected into adipose tissue (body fat) from various sources. It found that ingredient declarations varied significantly from one sample to another and were misleading.
The packaging states that “Lemon Bottle” contains mainly bromelain, lecithin and riboflavin, as well as a series of natural ingredients. But when Swissmedic conducted tests, it found that the composition did not correspond to the declaration, with some samples containing none of the ingredients indicated on the packaging.
As the quality of the ingredients is not controlled, the use of “Lemon Bottle” may present health risks, Swissmedic warns. It points out that any product that can be injected under the skin, such as “Lemon Bottle”, falls into the category of medicinal products subject to authorisation and may not be marketed as a cosmetic product.
Adapted from French by DeepL/sb
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles.
If you want to know more about how we work, have a look here, and if you have feedback on this news story please write to english@swissinfo.ch.
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
Swisscom records over 200 million cyberattacks per month
This content was published on
Swiss state-owned telecommunications provider Swisscom has to defend against 200 million cyberattacks on its own infrastructure every month.
This content was published on
International Women's Rights Day saw some 4,800 demonstrators march in the Swiss cities of Lausanne and Geneva on Saturday.
Diversity and equality ‘under threat’: ex-Swiss minister
This content was published on
Dismantling diversity programmes is a backwards step for equality, warns former Swiss government minister Simonetta Sommaruga.
Swiss regulator fines US bank Citi over fat-finger crash
This content was published on
Citigroup fined CHF500,000 by Swiss stock exchange regulator after a fat-finger trade caused a 2022 flash crash in European stocks.
This content was published on
Erection enhancers are the most frequently illegally imported medicines to Switzerland, followed by sleeping pills and sedatives.
Swiss medicine regulator warns against purchase of fake Ozempic
This content was published on
Swissmedic warns against the purchase of drugs from unknown sources after reports of hospitalisations due to fake Ozempic pens.
Pharma obesity market: Roche seeks deals to challenge Lilly and Novo
This content was published on
Roche isn’t done making moves in the obesity market after last month’s agreement to buy Carmot Therapeutics Inc. for $3.1 billion (CHF2.64 billion).
Swiss alliance calls for obesity to be recognised as a disease
This content was published on
The Swiss Obesity Alliance wants to classify obesity as a disease in the revision of the national strategy on “non-communicable diseases”.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.